Published in J Immunol on October 01, 1984
Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev (1997) 14.63
Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins. Infect Immun (1986) 6.92
Factors promoting acute and chronic diseases caused by yersiniae. Clin Microbiol Rev (1991) 4.53
LcrD, a membrane-bound regulator of the Yersinia pestis low-calcium response. J Bacteriol (1991) 3.43
Plague bacteria target immune cells during infection. Science (2005) 3.32
Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun (1993) 3.16
Differential clearance and host-pathogen interactions of YopE- and YopK- YopL- Yersinia pestis in BALB/c mice. Infect Immun (1989) 2.45
Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun (1995) 2.43
A low-Ca2+ response operon encodes the V antigen of Yersinia pestis. Infect Immun (1986) 2.39
The Yersinia pestis V antigen is a regulatory protein necessary for Ca2(+)-dependent growth and maximal expression of low-Ca2+ response virulence genes. J Bacteriol (1991) 2.30
Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun (1994) 2.26
Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun (2003) 2.20
Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun (1996) 2.17
Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun (1995) 2.04
Plasmid-determined cytotoxicity in Yersinia pestis and Yersinia pseudotuberculosis. Infect Immun (1986) 1.83
Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun (1997) 1.77
Yersinia pestis LcrV forms a stable complex with LcrG and may have a secretion-related regulatory role in the low-Ca2+ response. J Bacteriol (1997) 1.71
Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines (2008) 1.71
LcrV plague vaccine with altered immunomodulatory properties. Infect Immun (2005) 1.57
Structure and regulation of the Yersinia pestis yscBCDEF operon. J Bacteriol (1992) 1.50
Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun (2005) 1.45
Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun (1997) 1.45
Immune defense against pneumonic plague. Immunol Rev (2008) 1.44
lcrR, a low-Ca2(+)-response locus with dual Ca2(+)-dependent functions in Yersinia pestis. J Bacteriol (1990) 1.41
Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vaccine Immunol (2007) 1.37
Physiological basis of the low calcium response in Yersinia pestis. Infect Immun (1994) 1.31
Humoral and cellular defense against intestinal murine infection with Yersinia enterocolitica. Infect Immun (1991) 1.28
The ADP-ribosylating toxin, AexT, from Aeromonas salmonicida subsp. salmonicida is translocated via a type III secretion pathway. J Bacteriol (2003) 1.25
CD8(+) T cells restrict Yersinia pseudotuberculosis infection: bypass of anti-phagocytosis by targeting antigen-presenting cells. PLoS Pathog (2009) 1.24
Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun (2008) 1.18
Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun (2008) 1.18
Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci U S A (2006) 1.15
Major stable peptides of Yersinia pestis synthesized during the low-calcium response. Infect Immun (1993) 1.13
Expression of the plague plasminogen activator in Yersinia pseudotuberculosis and Escherichia coli. Infect Immun (1999) 1.10
Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria. Front Microbiol (2011) 1.03
The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response. J Intensive Care (2014) 0.99
Biofilm formation is not required for early-phase transmission of Yersinia pestis. Microbiology (2010) 0.98
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine (2008) 0.97
Amino acid residues 196-225 of LcrV represent a plague protective epitope. Vaccine (2009) 0.93
Biophysical characterization of Chlamydia trachomatis CT584 supports its potential role as a type III secretion needle tip protein. Biochemistry (2009) 0.92
A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. Vaccine (2011) 0.88
An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague. PLoS Negl Trop Dis (2012) 0.85
Role of antibodies in the opsonization of Yersinia spp. Infect Immun (1988) 0.85
Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes. Infect Immun (1998) 0.84
Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect Immun (2008) 0.84
In vitro expression of a 22-kilodalton Yersinia pestis polypeptide immunologically related to the 25-kilodalton plasmid-encoded protein of the three pathogenic Yersinia species. Infect Immun (1988) 0.82
Comparison of crossed immunoelectrophoresis, enzyme-linked immunosorbent assays, and tube agglutination for serodiagnosis of Yersinia enterocolitica serotype O:3 infection. J Clin Microbiol (1991) 0.80
LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague. Infect Immun (2014) 0.79
Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy. Microb Pathog (2010) 0.79
A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection. Infect Immun (2014) 0.78
Serum opsonic capacity against Yersinia enterocolitica O:3 in yersiniosis patients with or without reactive arthritis. Clin Exp Immunol (1989) 0.78
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
The genus Yersinia: biochemistry and genetics of virulence. Curr Top Microbiol Immunol (1972) 6.32
Plasmids in Yersinia pestis. Infect Immun (1981) 6.22
Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis. Proc Natl Acad Sci U S A (2004) 5.09
Plague virulence antigens from Yersinia enterocolitica. Infect Immun (1980) 4.83
Cytoplasmic and membrane proteins of yersiniae cultivated under conditions simulating mammalian intracellular environment. Proc Natl Acad Sci U S A (1981) 4.43
In vivo comparison of avirulent Vwa- and Pgm- or Pstr phenotypes of yersiniae. Infect Immun (1984) 4.16
Pasteurella pestis: Role of Pesticin I and Iron in Experimental Plague. Science (1965) 3.90
Vwa+ phenotype of Yersinia enterocolitica. Infect Immun (1983) 3.72
Accumulation of iron by yersiniae. J Bacteriol (1979) 3.40
Pesticins. 3. Expression of coagulase and mechanism of fibrinolysis. J Bacteriol (1967) 3.27
Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun (1993) 3.16
Determination of genome size, macrorestriction pattern polymorphism, and nonpigmentation-specific deletion in Yersinia pestis by pulsed-field gel electrophoresis. J Bacteriol (1992) 3.06
Studies on the pathogenicity of Yersinia enterocolitica. I. Experimental infection in rabbits. Microbiol Immunol (1977) 2.99
Studies on the pathogenicity of Yersinia enterocolitica. II. Interaction with cultured cells in vitro. Microbiol Immunol (1977) 2.96
Consequences of Ca2+ deficiency on macromolecular synthesis and adenylate energy charge in Yersinia pestis. J Bacteriol (1979) 2.91
Mutation rate to nonpigmentation in Pasteurella pestis. J Bacteriol (1969) 2.58
Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun (1995) 2.43
Effect of exogenous nucleotides on Ca2+ dependence and V antigen synthesis in Yersinia pestis. Infect Immun (1982) 2.32
Localization in Yersinia pestis of peptides associated with virulence. Infect Immun (1982) 2.26
Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun (1994) 2.26
Structural organization of virulence-associated plasmids of Yersinia pestis. J Bacteriol (1998) 2.22
Plasminogen activator/coagulase gene of Yersinia pestis is responsible for degradation of plasmid-encoded outer membrane proteins. Infect Immun (1988) 2.15
Growth of Pasteurella pseudotuberculosis in simulated intracellular and extracellular environments. J Infect Dis (1967) 2.06
The Vwa+ virulence factor of yersiniae: the molecular basis of the attendant nutritional requirement for Ca++. Rev Infect Dis (1983) 2.02
Characterization of pesticin. Separation of antibacterial activities. J Biol Chem (1974) 1.85
Resistance to pesticin, storage of iron, and invasion of HeLa cells by Yersiniae. Infect Immun (1987) 1.80
Roles of V antigen in promoting virulence in Yersiniae. Contrib Microbiol Immunol (1987) 1.70
Isoforms of caveolin-1 and caveolar structure. J Cell Sci (2000) 1.65
Studies on the pathogenicity of Yersinia enterocolitica. III. Comparative studies between Y. enterocolitica and Y. pseudotuberculosis. Microbiol Immunol (1977) 1.64
Correlation between epithelial cell infectivity in vitro and O-antigen groups of Yersinia enterocolitica. Microbiol Immunol (1977) 1.64
Characterization of enterobacteria by starch-gel electrophoresis of glucose-6-phosphate dehydrogenase and phosphogluconate dehydrogenase. J Bacteriol (1967) 1.64
Specificity, induction, and absorption of pesticin. J Bacteriol (1972) 1.48
Post-translational regulation of Lcr plasmid-mediated peptides in pesticinogenic Yersinia pestis. Microb Pathog (1987) 1.47
Mutations to tolerance and resistance to pesticin and colicins in Escherichia coli phi. J Bacteriol (1981) 1.46
Effect of Ca2+ on morphology and division of Yersinia pestis. Infect Immun (1974) 1.46
Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli. J Bacteriol (1973) 1.45
Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun (1997) 1.45
Outer membrane peptides of Yersinia pestis mediating siderophore-independent assimilation of iron. Biol Met (1989) 1.43
Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob Agents Chemother (1989) 1.39
Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother (1989) 1.34
In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin. J Antimicrob Chemother (1990) 1.32
Physiological basis of the low calcium response in Yersinia pestis. Infect Immun (1994) 1.31
Mode of action of pesticin: N-acetylglucosaminidase activity. J Bacteriol (1979) 1.28
Effect of ca on the synthesis of deoxyribonucleic Acid in virulent and avirulent yersinia. Infect Immun (1971) 1.27
Iron uptake and iron-repressible polypeptides in Yersinia pestis. Infect Immun (1996) 1.24
Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Infect Immun (1982) 1.22
RNA synthesis in Yersinia pestis during growth restriction in calcium-deficient medium. J Bacteriol (1982) 1.21
V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague. Infect Immun (1996) 1.20
Storage reservoirs of hemin and inorganic iron in Yersinia pestis. Infect Immun (1993) 1.19
Modulation of the low-calcium response in Yersinia pestis via plasmid-plasmid interaction. Microb Pathog (1987) 1.18
Mechanisms of bacterial virulence. Annu Rev Microbiol (1985) 1.17
Observations on the correlation between pathogenicity and serovars of Yersinia enterocolitica by the assay applying cell culture system and experimental mouse infection. Contrib Microbiol Immunol (1979) 1.17
Consequences of aspartase deficiency in Yersinia pestis. J Bacteriol (1978) 1.15
Expression of the low calcium response in Yersinia pestis. Microb Pathog (1989) 1.13
GLUCOSE-6-PHOSPHATE DEHYDROGENASE AND 6-PHOSPHOGLUCONATE DEHYDROGENASE ACTIVITIES OF PASTEURELLA PESTIS AND PASTEURELLA PSEUDOTUBERCULOSIS. J Bacteriol (1962) 1.11
Effect of calcium on the cell infectivity of virulent Shigella flexneri 2a. Jpn J Microbiol (1974) 1.11
Preparation of monoclonal antibody to V antigen from Yersinia pestis. Contrib Microbiol Immunol (1991) 1.11
Antimicrobial evaluation of cefoxitin: a new semisynthetic cephamycin. Comparative studies with cefazolin and cefalotin. Arzneimittelforschung (1977) 1.11
Characterization of deoxyribonucleic acid from Yersinia pestis by ethidium bromide-cesium chloride density gradient centrifugation. Infect Immun (1972) 1.10
Divalent cation stimulation of the cell infectivity of Shigella flexneri 2a. Jpn J Microbiol (1975) 1.10
Expression of the plague plasminogen activator in Yersinia pseudotuberculosis and Escherichia coli. Infect Immun (1999) 1.10
Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother (1991) 1.07
Stimulation of non-specific host resistance against Sendai virus and Escherichia coli infections by chitin derivatives in mice. Vaccine (1987) 1.05
Structure of O-specific side chains of lipopolysaccharides from Yersinia pseudotuberculosis. J Bacteriol (1974) 1.05
Application of cell culture in studying antibacterial activity of rifampicin to Shigella and enteropathogenic Escherichia coli. Jpn J Microbiol (1972) 0.99
Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine. Infect Immun (1983) 0.97
Mutagenic properties of cis-plantinum(II)diammino-dichloride in Escherichia coli. Mutat Res (1975) 0.97
Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog. Infect Immun (1982) 0.96
Structural studies of the O-specific side-chains of the lipopolysaccharide from Yersinia enterocolitica Ye 128. Carbohydr Res (1980) 0.96
Pesticin-dependent generation of somotically stable spheroplast-like structures. J Bacteriol (1978) 0.95
Transport of Ca2+ by Yersinia pestis. J Bacteriol (1987) 0.93
Molecular characterization of KatY (antigen 5), a thermoregulated chromosomally encoded catalase-peroxidase of Yersinia pestis. J Bacteriol (1999) 0.93
Metabolism of carbohydrates by Pasteurella pseudotuberculosis. J Bacteriol (1968) 0.92
Chemotherapeutic efficacy of ofloxacin on renal and subcutaneous infection models with Staphylococcus aureus in mice. Chemotherapy (1986) 0.90
Structural studies on the O-specific side-chains of the cell-wall lipopolysaccharide from Pasteurella pseudo-tuberculosis Group II B. Acta Chem Scand (1972) 0.89
Enhancement of non-specific resistance to Pseudomonas pneumonia by a synthetic derivative of muramoyl dipeptide in immunosuppressed guinea pigs. J Gen Microbiol (1982) 0.88
Detection of Yersinia pestis by pesticin fluorogenic probe-coupled PCR. Mol Cell Probes (2000) 0.86
Structural studies on the O-specific side-chains of the cell-wall lipopolysaccharide from Pasteurella pseudo-tuberculosis Group II A. Acta Chem Scand (1972) 0.86
Maternal origin of a unique extra chromosome, der(9)(pter-->q13::q13-->q12:) in a girl with typical trisomy 9p syndrome. Am J Med Genet (2001) 0.86
Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther (1993) 0.85
Stimulation of non-specific resistance to infection by muroctasin. Arzneimittelforschung (1988) 0.85
In vitro activity of DQ-2556, a new cephalosporin. Antimicrob Agents Chemother (1986) 0.84
Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog. Infect Immun (1982) 0.84
Protective role of complement in the development of experimental pneumococcal pneumonia in mice. Chemotherapy (1990) 0.83
In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1985) 0.83
Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice. Arzneimittelforschung (1988) 0.82
Inhibition of cell to cell transfer of Shigella by treatment with some antibiotics. Jpn J Microbiol (1973) 0.82
Chemotherapeutic evaluation of rifampicin to experimental bacillary dysentery in cynomolgus monkeys. Jpn J Microbiol (1972) 0.81
Virulence of rifampicin-resistant mutants of Shigella and enteropathogenic Escherichia coli with special reference to their cell invasiveness. Jpn J Microbiol (1973) 0.81
Nonbacteremic pseudomonas pneumonia in immunosuppressed guinea pigs. Microbiol Immunol (1982) 0.79
Influence of chromosome integrity on Escherichia coli cell division. J Bacteriol (1980) 0.79
Suppression of mouse skin allograft rejection by protein A-Yersiniae V antigen fusion peptide. Transplantation (1997) 0.79
Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. Arzneimittelforschung (1989) 0.78
Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. Neuroreport (2003) 0.78
Restoration by MDP-Lys (L18) of resistance to Pseudomonas pneumonia in immunosuppressed guinea pigs. Microbiol Immunol (1984) 0.78
Stimulation of macrophages by muroctasin to produce colony-stimulating factors. Arzneimittelforschung (1990) 0.77
Effect of cis-platinum(II)diamminodichloride on cell division of Hyphomicrobium and Caulobacter. J Bacteriol (1976) 0.77
Influence of unsaturation of fibrinolytic activity of salts of fatty acids. Proc Soc Exp Biol Med (1967) 0.77